August 29, 2026
RESEARCH USE ONLY. Products discussed on this site are supplied strictly for laboratory and research purposes. Nothing on this page is medical advice or a dosing recommendation for any person or animal. Both compounds named here are FDA-approved prescription medicines; that fact is reported below, not offered as guidance.
This is the one comparison in the incretin space that does not require hedging about indirect evidence. Two randomised head-to-head trials have been published, both with confidence intervals, both funded by the manufacturer of the winning arm — which is worth stating up front and holding in mind throughout.
Sourced fact: In SURPASS-2, a 40-week open-label Phase 3 trial in 1,879 adults with type 2 diabetes, tirzepatide was compared directly against semaglutide 1 mg. “Estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were −0.15 percentage points (95% CI, −0.28 to −0.03; P=0.02), −0.39 percentage points (95% CI, −0.51 to −0.26; P<0.001), and −0.45 percentage points (95% CI, −0.57 to −0.32; P<0.001)” for change in glycated hemoglobin. “Tirzepatide at all doses was noninferior and superior to semaglutide.” [1]
Sourced fact: In SURMOUNT-5, a 72-week open-label Phase 3b trial in 751 adults with obesity but without type 2 diabetes, “the least-squares mean percent change in weight at week 72 was −20.2% (95% CI, −21.4 to −19.1) with tirzepatide and −13.7% (95% CI, −14.9 to −12.6) with semaglutide (P<0.001).” [2]
Inference: On the metabolic endpoints these two trials measured, tirzepatide outperformed semaglutide, and the confidence intervals do not overlap in SURMOUNT-5. That is about as clean a comparative result as this field produces. It is also not the whole picture — see the cardiovascular section below.
1. The comparator doses were not both maximal. SURPASS-2 compared tirzepatide up to 15 mg against semaglutide 1 mg, which is the maximum approved Ozempic dose for glycemic control but below the 2.4 mg used for weight management. SURMOUNT-5 used “the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg)” [2] — so the obesity trial did compare at maximal doses, and the diabetes trial did not.
2. Both trials were open-label. Both publications state this in their methods. Unblinded trials of subjective-symptom-heavy interventions carry known limitations.
3. Both were funded by Eli Lilly, tirzepatide’s manufacturer. Stated in both abstracts.
This is the part that comparison tables built around weight percentages consistently omit.
Sourced fact: In SELECT, 17,604 patients with preexisting cardiovascular disease and BMI ≥27 but no diabetes were randomised to semaglutide 2.4 mg or placebo. “A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001).” [3]
Sourced fact: The Wegovy label carries a corresponding indication: “to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.” [4]
Sourced fact: Neither tirzepatide label carries a cardiovascular risk-reduction indication. Zepbound’s indications are weight reduction and moderate-to-severe obstructive sleep apnea in adults with obesity; Mounjaro’s is glycemic control in type 2 diabetes. [5] [6]
Sourced fact: A 2026 narrative review states the position plainly: “Tirzepatide demonstrates superior metabolic efficacy in direct comparative trials, whereas semaglutide currently has the strongest evidence for cardiovascular benefit,” and adds that “while contextual data confirms cardiovascular safety for tirzepatide against dulaglutide, definitive head-to-head cardiovascular outcomes comparing the two agents directly remain unestablished.” [7]
Inference: These two compounds lead on different endpoints. Tirzepatide leads on weight and HbA1c in direct comparison. Semaglutide leads on demonstrated cardiovascular outcomes and on breadth of approved indications. A page that reports only the first has told you half of what the literature contains.
| Product | Molecule | Indications on the current label |
|---|---|---|
| Mounjaro | Tirzepatide | Glycemic control in T2D, adults and pediatric patients 10+ [6] |
| Zepbound | Tirzepatide | Weight reduction and maintenance; moderate-to-severe OSA in adults with obesity [5] |
| Ozempic | Semaglutide | Glycemic control in T2D; MACE risk reduction in T2D with established CVD; reduced risk of sustained eGFR decline, ESKD and CV death in T2D with CKD [8] |
| Wegovy | Semaglutide | MACE risk reduction; weight reduction in adults and patients 12+; noncirrhotic MASH with F2–F3 fibrosis (accelerated approval) [4] |
Sourced fact: The MASH indication for Wegovy was granted 15 August 2025 under accelerated approval, and the label states: “Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.” [4]
Sourced fact: Both molecules carry the same class boxed warning regarding rodent thyroid C-cell tumors and contraindication in personal or family history of medullary thyroid carcinoma or MEN 2. [6]
Sourced fact: Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist, characterised in its pharmacology paper as showing “equal affinity for the GIPR compared with native GIP but binds the GLP-1R with approximately 5-fold weaker affinity than native GLP-1,” and as “a potent, partial agonist (51% efficacious) at the GLP-1R, while retaining full agonism at the GIPR.” [9]
Sourced fact: The same paper reports that tirzepatide “shows bias at the GLP-1 receptor to favor cAMP generation over β-arrestin recruitment, coincident with a weaker ability to drive GLP-1 receptor internalization compared with GLP-1.” [9]
Inference: The mechanistic difference is the GIP receptor arm. Whether that arm is the reason for the observed efficacy difference is a reasonable hypothesis, not a demonstrated causal claim — and it sits inside an active scientific debate about whether GIPR agonism or antagonism is beneficial at all, which we cover in our GLP-1 vs GIP explainer.
Sourced fact (SURPASS-2): “The most common adverse events were gastrointestinal (nausea, 17 to 22% with tirzepatide and 18% with semaglutide; diarrhea, 13 to 16% vs 12%; vomiting, 6 to 10% vs 8%).” The same abstract reports: “Serious adverse events were reported in 7% of patients who received tirzepatide and 3% of those who received semaglutide.” [1]
Sourced fact (SELECT): “Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001).” [3]
Inference: Common GI adverse events were broadly similar in the direct diabetes comparison. The serious-adverse-event figure — 7% versus 3% — runs in the opposite direction to the efficacy result and is rarely quoted alongside it.
What we could not verify: per-event adverse-event frequencies for SURMOUNT-1 and SURMOUNT-5; those abstracts report discontinuation rates but not individual event rates.
This is not medical advice and not a recommendation of either medicine. Both are prescription products; decisions about them belong with a licensed physician. This page reports what two randomised head-to-head trials measured, what four FDA labels say, and where the evidence points in different directions depending on which endpoint you ask about.
PureLab Performance supplies tirzepatide for laboratory research use. Every compound page publishes its own specification block — lot, chromatographic purity, label claim, identity method and testing laboratory — or states plainly that the certificate is pending. Related: what is tirzepatide · what is semaglutide · retatrutide vs tirzepatide.
RESEARCH USE ONLY — FULL DISCLAIMER. The products discussed on this page are supplied strictly for laboratory and scientific research purposes. They are not for human or veterinary use, and not for consumption. These statements have not been evaluated by the Food and Drug Administration. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease in humans or animals. Nothing here constitutes medical or veterinary advice or a dosing, preparation, or administration recommendation for any person or animal.
Label text and indications verified against DailyMed on 19–20 August 2026.
